Search results for " malattie."

showing 10 items of 1941 documents

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

2020

Abstract Objectives To describe: (i) factors associated with rapid and delayed ART initiation; (ii) rates of 12 week virological response; and (iii) virologically controlled retention in care by 1 year from ART initiation according to timing of start in a real-life setting. Methods All individuals in the Icona cohort diagnosed with HIV in 2016–17 who initiated ART were grouped according to the time between HIV diagnosis and ART initiation: Group 1, ≤7 days; Group 2, 8–14 days; Group 3, 15–30 days; Group 4, 31–120 days; and Group 5, >120 days. Multivariable logistic regression models were used to identify factors associated with: (i) the probability of rapid (Group 1) and very delayed…

0301 basic medicinediagnosishivcommunicable diseasesHIV InfectionsLogistic regressionVirological responseCohort Studies0302 clinical medicineRetention in CareMedicinePharmacology (medical)HIV Infection030212 general & internal medicineProspective cohort studycd4 count determination proceduredrugsuppressionViral LoadCD4 Lymphocyte Count; Cohort Studies; Humans; Italy; Viral Load; Anti-HIV Agents; HIV Infections; Retention in CarevirologyInfectious DiseasesItalyblood hiv rnaCohorthiv cd4 count determination procedure communicable diseases incomeitaly diagnosis virology blood hiv rna retention in careincomeitalyViral loadHIV ARTCohort studyHumanMicrobiology (medical)medicine.medical_specialtyAnti-HIV Agentsantiretroviral therapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesHIV viral loadInternal medicineHumansHIV CD4 ARTPharmacologybusiness.industrydouble blindAnti-HIV AgentHIV viral load antiretroviral therapy double blind initiation suppression infectionRetention in care030112 virologyinfectioninitiationCD4 Lymphocyte CountObservational studyCohort Studiebusiness
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis.

2020

Invasive aspergillosis (IA) is a life-threatening infection that affects an increasing number of patients undergoing chemotherapy or allo-transplantation, and recent studies have shown that genetic factors contribute to disease susceptibility. In this two-stage, population-based, case-control study, we evaluated whether 7 potentially functional single nucleotide polymorphisms (SNPs) within the ARNT2 and CX3CR1 genes influence the risk of IA in high-risk hematological patients. We genotyped selected SNPs in a cohort of 500 hematological patients (103 of those had been diagnosed with proven or probable IA), and we evaluated their association with the risk of developing IA. The association of …

0301 basic medicinehost immunityGenotype030106 microbiologyImmunologyPopulationCX3C Chemokine Receptor 1Single-nucleotide polymorphismARNT2 ; CX3CR1 ; genetic susceptibility; host immunity; invasive aspergillosisBiologyAspergillosisMicrobiologyPolymorphism Single NucleotideRisk Assessment03 medical and health sciencesCX3CR1GenotypemedicineGenetic predispositionBasic Helix-Loop-Helix Transcription FactorsHumansGenetic Predisposition to DiseaseARNT2AlleleeducationInvasive Pulmonary Aspergillosiseducation.field_of_studyinvasive aspergillosisHaplotypeAryl Hydrocarbon Receptor Nuclear TranslocatorPCRAGA Study Groupmedicine.diseaseHematologic Diseases3. Good healthSettore MED/15 - MALATTIE DEL SANGUE030104 developmental biologyInfectious DiseasesAspergillusCase-Control StudiesExpression quantitative trait lociImmunologyParasitologygenetic susceptibility
researchProduct

PFN1 and integrin‐β1/mTOR axis involvement in cornea differentiation of fibroblast limbal stem cells

2019

Abstract Ex vivo limbal stem cell transplantation is the main therapeutic approach to address a complete and functional re‐epithelialization in corneal blindness, the second most common eye disorder. Although important key points were defined, the molecular mechanisms involved in the epithelial phenotype determination are unclear. Our previous studies have demonstrated the pluripotency and immune‐modulatory of fibroblast limbal stem cells (f‐LSCs), isolated from the corneal limbus. We defined a proteomic profile especially enriched in wound healing and cytoskeleton‐remodelling proteins, including Profilin‐1 (PFN1). In this study we postulate that pfn‐1 knock down promotes epithelial lineage…

0301 basic medicinelimbal stem cellApoptosisintegrin-β1Settore MED/13 - EndocrinologiaProfilins0302 clinical medicinesignallingCells CulturedCorneal epitheliumIntegrin beta1TOR Serine-Threonine KinasesEpithelium CornealCell DifferentiationCell biologymedicine.anatomical_structuremTOR pathway030220 oncology & carcinogenesisMolecular MedicineOriginal ArticleStem cellHomeobox protein NANOGintegrin‐β1regenerative medicineBiologyLimbus CorneaeCorneal limbus03 medical and health sciencesstem cellsmedicineHumansprofilinFibroblastlimbal stem cellsPI3K/AKT/mTOR pathwayCell ProliferationWound HealingSettore MED/30 - Malattie Apparato VisivoCell BiologyOriginal ArticlesFibroblastseye diseasesepithelial differentiation030104 developmental biologyGene Expression RegulationEye disordersense organscorneal regenerationWound healingBiomarkersJournal of Cellular and Molecular Medicine
researchProduct

Behavioral and clinical characteristics of people receiving medical care for HIV infection in an outpatient facility in Sicily, Italy

2016

Paola Di Carlo,1 Giuliana Guadagnino,1 Palmira Immordino,1 Giovanni Mazzola,2 Pietro Colletti,2 Ilenia Alongi,1 Lucia Adamoli,1 Francesco Vitale,1 Alessandra Casuccio1 1Department of Sciences for Health Promotion and Mother-Child Care “G D’Alessandro”, University of Palermo, 2Department of Medicinal Clinics and Emerging Diseases, “Paolo Giaccone” Polyclinic University Hospital, Palermo, Italy Aim: The authors examined a cohort of HIV-positive outpatients at the AIDS Center of Palermo University in Italy in order to identify factors related to the frequency of their visits to the outpatient facility for health care services.Methods: Two hundr…

0301 basic medicinemedicine.medical_specialtyMultivariate analysisSettore MED/17 - Malattie Infettivehard-to-reach groups030106 microbiologyHuman immunodeficiency virus (HIV)Medicine (miscellaneous)HIV Outpatient Servicemedicine.disease_causeSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineOutpatient facilityAmbulatory careAcquired immunodeficiency syndrome (AIDS)CD4+ T-cell countHealth careMedicine030212 general & internal medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)Access to care; CD4+ T-cell count; Hard-to-reach groups; HIV infection; HIV outpatient service; Resource use; Social Sciences (miscellaneous); Medicine (miscellaneous); Health Policy; Pharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchaccess to carelcsh:R5-920business.industryHealth PolicyUnivariatemedicine.diseaseHIV infectionresource usePatient Preference and AdherenceEmergency medicineCohortbusinesslcsh:Medicine (General)Hard-to-reach groupSocial Sciences (miscellaneous)
researchProduct

The Burden of Respiratory Syncytial Virus Disease in Pre-Term Infants

2015

This mini-review summarises the risk factors for acquiring Respiratory Syncitial Virus (RSV) infection, and describes the harmful effects of the infection in pre-term infants. Moreover, theoretical considerations are discussed for the prevention of RSV infection in high-risk infant categories, such as pre-term infants. Background: Neonates positive for RSV are more prone to severe infection than neonates infected with other common respiratory viruses. Despite RSV infection being more common in late neonates than in early ones, pre-term infants ≤ 35 wk gestational age (GA) are at high risk for developing severe RSV disease. Efforts to prevent infection include case management, vaccination an…

0301 basic medicinemedicine.medical_specialtyPediatricsibandronateEnvironmental EngineeringSettore MED/17 - Malattie Infettivebusiness.industryVirus diseasesKeywords : OvariectomyIndustrial and Manufacturing EngineeringTerm (time)anti-oxidant enzyme03 medical and health sciences030104 developmental biology0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaestradiolrat’s liver.medicine030212 general & internal medicineRespiratory systemIntensive care medicinebusinessOvariectomy; estradiol; ibandronate; anti-oxidant enzymes; DEPPD free radical; rat’s liver. [Keywords]DEPPD free radical
researchProduct

Vancomycin resistant Enterococcus faecium (VRE) vertebral osteomyelitis after uneventful spinal surgery: A case report and literature review

2017

Abstract Objective Case report and literature review. Background Enterococcus faecium is an emerging pathogen responsible for post procedural infections in patients who have undergone spinal decompression surgery. In this case report, the authors discuss and review recent literature on approaches to post-operative spinal infection. Case report We herein report the case of a 55-year-old HIV-negative Caucasian Italian woman who showed vertebral osteomyelitis with abscesses around the interbody cage caused by an Enterococcus faecium vancomycin resistant gen-Van A, following a Transforaminal Lumbar Interbody Fusion (TLIF). The same strain was detected in disc biopsy, urine culture and rectal sw…

0301 basic medicinemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaEnterococcus faecium; Spinal surgery; Transforaminal Lumbar Interbody Fusion (TLIF); Vertebral osteomyelitis; Surgery; Neurology (clinical)Settore MED/17 - Malattie Infettive030106 microbiologyEnterococcus faeciumlcsh:Surgerylcsh:RC346-42903 medical and health sciencesEmerging pathogen0302 clinical medicineAntibiotic resistanceVertebral osteomyelitisBiopsymedicineVertebral osteomyelitislcsh:Neurology. Diseases of the nervous systemVancomycin resistant Enterococcus faeciumTransforaminal Lumbar Interbody Fusion (TLIF)medicine.diagnostic_testbiologybusiness.industrySettore MED/27 - Neurochirurgialcsh:RD1-811biology.organism_classificationmedicine.diseaseSpinal surgerySurgerySurgeryImplantSpinal surgeryNeurology (clinical)Vertebral osteomyelitibusiness030217 neurology & neurosurgeryEnterococcus faeciumInterdisciplinary Neurosurgery
researchProduct

Successful management of a cerebral abscess secondary to chronic cholesteatoma caused by Prevotella melaninogenica and Peptococcus anaerobius – A cas…

2016

Abstract Cerebral abscess following cholesteatomatous otomastoiditis is a life-threatening complication and poses diagnostic and therapeutic challenges. We report a case of life-threatening cerebritis and cerebral abscess due to a collection of pus from an aerobic super infections occurring months after the apparent resolution of an otogenic brain abscess in a 67-year-old immunocompetent Italian female. Two gram-positive anaerobic pathogens were isolated during secondary neurosurgical procedures and antibiotic treatment was adopted to resolve the complications. Another objective of this study was to review the literature on gram-positive anaerobic pathogens and brain abscess complications i…

0301 basic medicinemedicine.medical_specialtySettore MED/17 - Malattie InfettiveFistula030106 microbiologylcsh:Surgerylcsh:RC346-429Surgery; Neurology (clinical)Prevotella melaninogenica03 medical and health sciences0302 clinical medicineMedicineAbscessBrain abscesslcsh:Neurology. Diseases of the nervous systembusiness.industrySettore MED/27 - NeurochirurgiaCholesteatomalcsh:RD1-811medicine.diseasebacterial infections and mycosesSurgeryInfectious disease (medical specialty)CerebritisSurgeryNeurology (clinical)medicine.symptombusinessComplication030217 neurology & neurosurgeryInterdisciplinary Neurosurgery
researchProduct

Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors

2019

Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study, we describe the management of 5 patients with chronic myeloid leukemia treated with ponatinib, from second to fourth line of tyrosine kinase inhibitor therapy, carrying high pre-ponatinib CV risk, who obtained optimal molecular response and developed no CV adverse event during follow-up. Among these 5 patients, 2 had diagnosis of ischemic heart disease and underwent percutaneous angioplasty, 2 had type 2 diabetes and arterial hype…

0301 basic medicinemedicine.medical_specialtymedicine.drug_class030106 microbiologyCardiovascular risk factorsType 2 diabetesDiseaseTyrosine-kinase inhibitorSettore MED/15 - Malattie Del Sangue03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientAdverse effectPharmacologybusiness.industryPonatinibChronic myeloid leukemiaMyeloid leukemiaGeneral Medicinemedicine.diseaseCardiovascular riskInfectious DiseasesOncologychemistry030220 oncology & carcinogenesisPonatinibbusiness
researchProduct

ARIA���EAACI statement on asthma and COVID���19 (June 2, 2020)

2021

Artículo con numerosos autores sólo se mencionan el primero y el de la UAM

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)AllergyStatement (logic)MedicinaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunology610Settore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_cause03 medical and health sciences0302 clinical medicineastmaMedicine and Health SciencesmedicineHumansImmunology and Allergy030212 general & internal medicineLetters to the EditorLetter to the Editorudc:616.2AsthmaCoronavirusScience & Technologybusiness.industrySARS-CoV-2virus diseasesCOVID-19asthmamedicine.diseaseVirologyAsthma3. Good health030228 respiratory systemcovid-191107 ImmunologyAngiotensin-Converting Enzyme 2businessARIA-EAACILife Sciences & Biomedicine600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct